PlainPharmaWatch

CMS Open Payments · Program Year 2024

Biocodex, Inc.

Biocodex, Inc. reported $24,977.44 across General Payments, Research, and Ownership to 333 physicians and teaching hospitals across 333 transactions.

$25.0K
All-tracks total
333
Transactions
333
Recipients
−$105.8K
General Payments vs PY2023

Biocodex, Inc. reported $24,977.44 across all CMS Open Payments tracks (General + Research + Ownership) to 333 physicians and teaching hospitals in Program Year 2024 - ranking #1496 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $24,977.44, averaging $75.01 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

CMS Sunshine Act warrant

Manufacturer biocodex-inc Biocodex, Inc.

$25.0K · #1496/1,925 · 0.0% industry · PY2024

  • TOT $25.0K
  • RANK #1496
  • SHARE 0.0%
  • TXN 333
  • RCP 333
  • CAT 3
  • GEN $25.0K
  • ΔGEN −$105.8K
  • TOP1 26.7%
  • PY 2024

Nearest volume peer: CIVCO Medical Instruments ($25.0K)

Topcon Corporation$25.2KAucta Pharmaceuticals, Inc.$25.2KCIVCO Medical Instruments$25.0KBiocodex, Inc. (this)$25.0KForthright Medical-AZ, LLC$24.7K
All-tracks payment totals near Biocodex, Inc. (CMS Open Payments PY2024)

Biocodex, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Biocodex, Inc.'s CMS-reported General Payments decreased by $105.8K (−80.9%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: BIOCODEX, INC.PY2023: BIOCODEX, INC.PY2024: BIOCODEX, INC.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$130.8KPY2024$25.0K
PY2023
$130,822.13
PY2024
$24,977.44

What the Data Shows for Biocodex, Inc.

In Program Year 2024, Biocodex, Inc. reported $24,977.44 in payments to 333 physicians and teaching hospitals across 333 individual transactions, an average of $75.01 per transaction and $75.01 per recipient. That total places Biocodex, Inc. at rank #1496 out of 1,925 companies in the CMS Open Payments database, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

321 transactions worth $16.4K make "Food and Beverage" the top general-payment category in the 3-category breakdown below, 65.6% of General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Biocodex, Inc. made 3 types of general payments. "Food and Beverage" is the largest category at $16.4K, 65.6% of General Payments.

How Biocodex, Inc. divides its payments

General-payment categories, ordered by reported total

1. Food and Beverage$16.4K2. Consulting Fee$7.4K3. Travel and Lodging$1.2K
Payment Type Amount Transactions
Food and Beverage $16.4K 321
Consulting Fee $7.4K 3
Travel and Lodging $1.2K 9

Recipient Concentration in General Payments

The five largest recipient relationships account for $10,256.81 (41.1%) of $24,977.44 in this company's General Payments records across 213 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Biocodex, Inc.

The five named recipients with the highest reported General Payments from this company

Jamie Wheless$6.7KMary Lynn Zupanc$2.3KMichael Chez$458.58Scott D Perry$455.58Raman Sankar$387.26
  1. 1

    Jamie Wheless

    $6,681.39 across 17 reported transactions

  2. 2

    Mary Lynn Zupanc

    $2,274.00 across 1 reported transactions

  3. 3

    Michael Chez

    $458.58 across 6 reported transactions

  4. 4

    Scott D Perry

    $455.58 across 8 reported transactions

  5. 5

    Raman Sankar

    $387.26 across 3 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Biocodex, Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Biocodex, Inc..

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Biocodex, Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

View saved (companies)
Download Biocodex, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.